Eli Lilly makes modest bet on 'all-in-human' discovery outfit for ALS drugs, deepening bid in precision neurology
For years, Big Pharma has retreated from neurology amid a series of high-profile failures in the big-ticket indications such as Alzheimer’s and ALS. But the tide has turned in recent years, and big drugmakers like Eli Lilly have doubled down on their investments in the space.
Now, looking to crack a new path to “precision neurology,” Lilly is putting its name behind a genomics player aiming for a novel path to neurological disease therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.